Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.

Gillessen S; Gilson C; James N; Adler A; Sydes MR; Clarke N

doi:10.1016/j.eururo.2016.07.015

Back

Journal article

Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.

Gillessen S Department of Oncology/Haematology, Kantonsspital, St. Gallen, Switzerland.
Gilson C MRC Clinical Trials Unit, University College London, London, UK.
James N Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK.
Adler A Diabetes Service, Addenbrooke's Hospital, Cambridge, UK.
Sydes MR MRC Clinical Trials Unit, University College London, London, UK.
Clarke N Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK. Electronic address: noel.clarke@christie.nhs.uk.

2016-07-25

Published in:

European urology. - 2016

English Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.

Language